問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Dermatology

Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Dermatology

更新時間：2023-09-19

林尚宏
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

63Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林尚宏

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Dermatology

List

81Cases

2025-07-18 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2028-09-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-06-01 - 2026-12-31

Phase III

Active
An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP)

  • Condition/Disease

    Generalized Pustular Psoriasis (GPP)

  • Test Drug

    Spesolimab (BI 655130)

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-12-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-08-01 - 2025-01-24

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2025-06-01 - 2034-08-15

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-10-10 - 2027-07-14

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2021-12-31

Phase III

A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable

  • Condition/Disease

    Neurodermatitis

  • Test Drug

    Dupilumab Dupilumab

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2019-04-01 - 2020-04-01

Phase I

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria

  • Condition/Disease

    Chronic Spontaneous Urticaria

  • Test Drug

    UB-221

Participate Sites
2Sites

Recruiting2Sites

2021-10-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

1 3 4 5 6 7 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB